Hepcidin and Ferritin Predict Microbial Etiology in Community-Acquired Pneumonia by Oppen, Kjersti et al.
M a j o r  a r t i c l e
Iron and Microbial Etiology • ofid • 1
Open Forum Infectious Diseases
 
Received 3 December 2020; editorial decision 10 February 2021; accepted 15 February 2021.
Correspondence: Kjersti Oppen, MD, Vestre Viken Hospital Trust, Dronninggata 28, 3004 
Drammen, Norway (kjeopp@vestreviken.no).
Open Forum Infectious Diseases®2021
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases 
Society of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the 
work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofab082
Hepcidin and Ferritin Predict Microbial Etiology in 
Community-Acquired Pneumonia
Kjersti Oppen,1,2,3,  Thor Ueland,2,3,4 William Ward Siljan,5 Øyvind Skadberg,6 Cato Brede,6,7 Trine Lauritzen,1 Pål Aukrust,2,3,4,8, Trude Steinsvik,1 
Einar Husebye,10 Annika E Michelsen,2,3 Jan Cato Holter,3,9 and Lars Heggelund10,11
1Department of Laboratory Medicine, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway, 2Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, 
3Institute of Clinical Medicine, University of Oslo, Oslo, Norway, 4Faculty of Health Sciences, K.G. Jebsen TREC, University of Tromsø, Tromsø, Norway, 5Division of Medicine, Akershus University Hospital, 
Lørenskog, Norway, 6Department of Medical Biochemistry, Stavanger University Hospital, Stavanger, Norway, 7Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, 
Stavanger, Norway, 8Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway, 9Department of Microbiology, Oslo University Hospital, Oslo, Norway, 
10Department of Internal Medicine, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway, 11Department of Clinical Science, Bergen Integrated Diagnostic Stewardship Cluster, Faculty of 
Medicine, University of Bergen, Bergen, Norway
Background. Iron is crucial for survival and growth of microbes. Consequently, limiting iron availability is a human antimicro-
bial defense mechanism. We explored iron and iron-related proteins as potential biomarkers in community-acquired pneumonia 
and hypothesized that infection-induced changes in these potential biomarkers differ between groups of pathogens and could pre-
dict microbial etiology.
Methods. Blood samples from a prospective cohort of 267 patients with community-acquired pneumonia were analyzed for 
hepcidin, ferritin, iron, transferrin, and soluble transferrin receptor at admission, clinical stabilization, and a 6-week follow-up. 
A total of 111 patients with an established microbiological diagnosis confined to 1 microbial group (atypical bacterial, typical bacte-
rial, or viral) were included in predictive analyses.
Results. High admission levels of ferritin predicted atypical bacterial versus typical bacterial etiology (odds ratio [OR], 2.26; 
95% confidence interval [CI], 1.18–4.32; P = .014). Furthermore, hepcidin and ferritin predicted atypical bacterial versus viral eti-
ology (hepcidin: OR = 3.12, 95% CI = 1.34–7.28, P = .008; ferritin: OR = 2.38, 95% CI = 1.28–4.45, P = .006). The findings were 
independent of C-reactive protein and procalcitonin.
Conclusions. Hepcidin and ferritin are potential biomarkers of microbial etiology in community-acquired pneumonia.
Keywords:  biomarkers; ferritin; hepcidin; iron; pneumonia.
Almost all organisms depend on iron to thrive, and the amount 
of iron available to microbes affects survival and growth and, 
thus, their pathogenic potential [1]. The human immune 
system has evolved various defense mechanisms to limit iron 
availability, resulting in an evolutionary battle for iron between 
microbes and host. Systemic iron homeostasis is predominantly 
orchestrated by hepcidin, a peptide hormone mainly produced 
in the liver [2]. Production of hepcidin changes rapidly and 
over a wide dynamic range in response to multiple stimuli [3]. 
Hepcidin is suppressed in response to increased physiological 
iron requirements and, conversely, induced by increased iron 
levels to prevent iron accumulation. In addition, as part of the 
inflammatory response to invading microbes, the hepcidin level 
rapidly increase in response to inflammatory cytokines, partic-
ularly interleukin 6 (IL-6) [4]. Still, how these opposing and 
converging signals are integrated to regulate hepcidin expres-
sion and maintain iron homeostasis is incompletely understood 
[3].
Hepcidin acts by inducing degradation of the ferroportin 
iron transporter, causing iron entrapment intracellularly and 
restricting access of iron to various microbes [5]. This may 
inhibit replication of typical extracellular bacteria, but it may 
also provide a nutritional advantage for atypical bacteria with 
intracellular growth [6]. Induction of hepcidin has also been 
demonstrated in viral infections, although the contribution to 
pathogenesis is largely unknown [5]. Knowledge of the var-
ious mechanisms involved and the interplay between pathogen 
and host is emerging, yet a comprehensive overview of the iron 
metabolism during infections is lacking. Specific differences in 
host responses to pathogens need to be explored both on indi-
vidual and group levels, including intracellular versus extracel-
lular pathogens [7].
Whereas hepcidin is a key iron regulator in plasma, fer-
ritin is the major iron storage protein and transferrin the 
main iron transport protein. As transferrin in plasma ex-
ceeds its iron binding capacity (assessed by transferrin 
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saturation; s-iron/s-total iron binding capacity), iron binds 
to citrate, other organic acids, and albumin, collectively 
termed nontransferrin-bound iron (NTBI) [8]. Cellular up-
take of transferrin-bound iron is mediated by transferrin 
receptor 1 via endocytosis according to cellular iron require-
ments [9]. Serum levels of the soluble form (s-transferrin 
receptor) are correlated to erytropoietic activity and tissue 
iron content [10].
During inflammation, various cytokines induce synthesis 
of ferritin, particularly in macrophages [7, 11]. Increased 
iron storage as ferritin in these cells reduces the labile iron 
pool intracellularly, which is believed to reduce the growth 
of intracellular pathogens. However, some pathogens have 
evolved strategies to overcome this defense mechanism [12]. 
In addition, ferritin has been hypothesized to leak from 
damaged cells during the inflammatory process, leading to 
higher systemic levels. Thus, it may serve as a marker of cel-
lular damage [13].
Because infections induce changes in levels of iron and iron-
related proteins that may differ among groups of pathogens, we 
explored the ability of these potential biomarkers to predict mi-
crobial etiology as well as their temporal dynamics in a cohort 
of hospitalized adult community-acquired pneumonia (CAP) 
patients.
MATERIALS AND METHODS
In this prospective cohort, adults (≥18  years) with suspected 
CAP admitted to Drammen hospital (Vestre Viken Hospital 
Trust, Norway) were recruited over a 3-year period (January 1, 
2008–January 31, 2011).
Patient Selection and Design
Community-acquired pneumonia diagnosis was established 
based on the following criteria within the first 48 hours of ad-
mission: (1) identification of a new pulmonary infiltrate on 
chest x-ray, (2) rectal temperature ≥38.0°C, and (3) at least 1 
of the following: productive or nonproductive cough, dyspnea, 
respiratory chest pain, crackles, or reduced respiratory sounds. 
Discharge from hospital within 2 weeks before admission or 
x-ray findings of other noninfectious pulmonary disease led 
to exclusion.
Criteria for clinical stabilization were evaluated daily for the 
first 12  days upon admission. C-reactive protein (CRP) and 
leucocytes were measured every second day. Clinical stabiliza-
tion was defined by at least 3 of the following 4 criteria: (1) un-
changed antibiotic treatment the last 2 days, (2) improvement 
of general condition, (3) morning rectal temperature <38°C, 
and (4) >25% decrease in CRP levels or leucocyte count. The 
participants were invited to a 6-week follow-up including blood 
sampling and a renewed chest x-ray.
Patient Consent Statement
All patients signed an informed consent form. The study was 
approved by the Regional Committee for Medical and Health 
Research Ethics in South-Eastern Norway (reference number 
S-06266a) and registered in ClinicalTrials.gov (NCT01563315).
Data Collection and Definitions
Clinical information was recorded on paper case records 
forms and extracted from medical records. All chest x-rays 
were re-examined by an experienced study radiologist 
blinded to the clinical data. Microbial etiology was estab-
lished through an extensive microbiological investigation 
as described elsewhere [14] and categorized as pure typical 
bacterial, pure atypical bacterial, pure viral, mixed, or no es-
tablished etiology. Pure etiology was defined as 1 or more 
pathogens identified within a particular group. Severity of ill-
ness was assessed by the clinical scoring tool CURB-65 (con-
fusion, urea, respiratory rate, blood pressure, age ≥65 years) 
[15] and by intensive care unit (ICU) admissions during the 
hospital stay. A CURB-65 score ≤2 was defined as low risk, 
and a score ≥3 was defined as high risk. Further details are 
available in previous publications [14, 16].
Sample Collection and Analysis
Blood samples were collected at admission (within 48 hours), 
clinical stabilization, and 6-week follow-up. Serum was allowed 
to clot for at least 30 minutes, and further preparation of serum 
and plasma was carried out within 60 minutes after sampling by 
refrigerated centrifugation at 2000 ×g for 12 minutes. Several 
aliquots were stored at −80°C.
Analysis were performed on all samples given sufficient mate-
rial. Analysis of plasma hepcidin was performed by liquid chro-
matography coupled with tandem mass spectrometry, which 
selectively measures the biological active isoform of hepcidin, 
hepcidin-25. This method has been validated for clinical appli-
cations at Stavanger University Hospital (Stavanger, Norway) 
according to Eurachem guidelines [17] and later revalidated 
as part of work in the Working Group on Clinical Quantitative 
Mass Spectrometry Proteomics of the International Federation 
of Clinical Chemistry. Samples used for hepcidin analysis had 
been through 1 freeze-thaw cycle before analysis. All samples 
were handled equally, and differences in serum hepcidin over 
4 freeze-thaw cycles have been reported to be of minor impor-
tance [18]. An international standard for hepcidin is not yet 
universally applied [19], hence comparisons between groups are 
more relevant than the absolute values. Levels of CRP, ferritin, 
iron, and transferrin were all analyzed in serum on Architect 
ci16200 (Abbott Diagnostics, Abbott Park, IL). Serum soluble 
transferrin receptor was analyzed on BN ProSpec (Siemens 
Healthineers, Marburg, Germany). Serum procalcitonin ([PCT] 
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was analyzed on ADVIA Centaur (Siemens Healthineers, 
Tarrytown, NY). C-reactive protein and PCT analysis are pre-
viously reported [20]. HFE gene variants were detected by pol-
ymerase chain reaction amplification and melt curve analysis 
on Lightcycler 480 (Roche Diagnostics, Oslo, Norway) using in 
vitro diagnostics kit from TIB MOLBIOL (Berlin, Germany).
Data Analysis
Categorical data are presented as n (%). Normally distributed 
continuous variables are presented as mean (standard deviation), 
whereas skewed data are presented as median (25–75 percentile). 
Multiple group comparisons were performed using one-way 
analysis of variance for normally distributed continuous vari-
ables. Multiple groups of categorical data were compared (1) by 
Pearson χ 2 or (2) by Fisher’s exact test if the expected count was 
<5 in >20% of the cells. Wilcoxon signed-rank test was used to 
compare levels at admission and 6-week follow-up. In statistical 
analysis predicting microbial etiology, patients with unknown 
microbial etiology or copathogens across etiological groups were 
excluded. Ln-transformation was applied to achieve normally 
distributed variables for logistic regression analysis. Predictive 
analysis was performed using bivariate logistic regression of the 
ln-transformed, standardized variables to estimate odds ratios 
(ORs) with 95% confidence intervals (CIs). A  2-sided signifi-
cance level of 0.05 was used in all analysis. Statistical analysis was 
performed using SPSS (version 25; IBM, Chicago, IL).
RESULTS
A total of 267 patients ≥18 years admitted to hospital with sus-
pected CAP were included out of 320 screened patients as detailed 
previously [14]. Median time from admission to clinical stabiliza-
tion was 4 days (range, 1–72). Among the survivors at the 6-week 
follow-up, 90% attended. For biomarker assessment, there were at 
the most 35, 61, and 43 missing values at admission, clinical stabi-
lization, and 6-week follow-up (missing due to deaths included).
Baseline Characteristics
Baseline characteristics are presented according to microbial 
etiology in Table 1, and an overview of the identified mi-
crobes is provided in Supplementary Table 1. An etiological 
diagnosis was established in 167 patients (63%) in which 69 
patients (41%) had more than 1 detected microbe, as previ-
ously published [14]. A  total of 111 patients had 1 etiolog-
ical diagnosis only, either pure typical bacterial, pure atypical 
bacterial, or pure viral. Within the typical bacterial group, 
Streptococcus pneumoniae was detected in a majority of the 




Pure Typical  
Bacterial (n = 51)
Pure Atypical  





No Established  
Etiology (n = 100)
P 
Value
Demographics        
Age in years, mean (SD) 64.4 (17.6) 64.7 (19.0) 55.5 (20.3) 66.5 (17.2) 63.3 (16.0) 63.6 (17.9) .18
Female gender, n (%) 127 (47.6) 26 (51.0) 8 (42.1) 20 (48.8) 24 (42.9) 49 (49.0) .90
Active smoker, n (%) 65 (24.4) 16 (32.0) 3 (15.8) 7 (17.1) 18 (32.1) 21 (21.0) .20
Nursing home resident, n (%) 4 (1.5) 1 (2.0) 0 2 (4.9) 0 1 (1.0) .34
Comorbid Conditions, n (%) 172 (64.4) 32 (62.7) 6 (31.6) 31 (75.6) 39 (69.6) 64 (64.0) .018
Cardiovascular diseasec 74 (27.7) 16 (31.4) 5 (26.3) 11 (26.8) 16 (28.6) 26 (26.0) .97
COPD 60 (22.5) 14 (27.5) 3 (15.8) 10 (24.4) 12 (21.4) 21 (21.0) .83
Immunocompromisedd 48 (18.0) 10 (19.6) 2 (10.5) 8 (19.5) 9 (16.1) 19 (19.0) .90
Autoimmune diseasee 34 (12.7) 10 (19.6) 0 4 (9.8) 7 (12.5) 13 (13.0) .26
Diabetes mellitus 33 (12.4) 6 (11.8) 1 (5.3) 7 (17.1) 9 (16.1) 10 (10.0) .56
Renal disease 32 (12.0) 6 (11.8) 2 (10.5) 4 (9.8) 11 (19.6) 9 (9.0) .42
Neurological diseasef 19 (7.1) 1 (2.0) 0 4 (9.8) 2 (3.6) 12 (12.0) .087
Dementia 15 (5.6) 4 (7.8) 2 (10.5) 2 (4.9) 1 (1.8) 6 (6.0) .47
Liver disease 4 (1.5) 1 (2.0) 0 0 1 (1.8) 2 (2.0) 1.00
Severity of Illness, n (%)        
CURB-65 ≥3 97 (37.9) 17 (34.7) 8 (42.1) 14 (35.9) 24 (44.4) 34 (35.8) .81
ICU admission 48 (18.0) 7 (13.7)  5 (26.3) 7 (17.1) 9 (16.1) 20 (20.0) .74
Abbreviations: COPD, chronic obstructive pulmonary disease; CURB-65, confusion, urea, respiratory rate, blood pressure, age ≥65 years; ICU, intensive care unit; SD, standard deviation.
a<5% missing data. 
bMix of at least 2 of the groups: typical bacterial, atypical bacterial, and viral. 
cHeart failure, coronary heart disease, cerebrovascular disease, peripheral artery disease. 
dPrimary or secondary immunodeficiency, active malignancy, immunosuppressive drugs. 
eRheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, autoimmune hepatitis, Sjogren’s disease, psoriasis. 
fCentral nervous disease, neuromuscular disease. 
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patients (82%). The only significant difference between the 
etiological groups in baseline characteristics was the overall 
count of comorbid conditions, with the lowest proportion in 
the atypical bacterial group.
Dynamics of Iron and Iron-Related Proteins During the Course of 
Community-Acquired Pneumonia
All potential biomarkers showed statistically significant differences 
in the acute-phase compared with the 6-week follow-up (Figure 
1). Whereas serum levels of iron, transferrin, transferrin satura-
tion, and soluble transferrin receptor increased during follow-up, 
serum levels of hepcidin and ferritin were highest at admission 
(6.3- and 3.9-fold change compared with the 6-week follow-up).
Association Between the Potential Biomarkers and Microbial Etiology
Comparing the 2 bacterial groups, admission levels of fer-
ritin were significantly higher in patients with atypical bacte-
rial etiology (Figure 2). Both hepcidin and ferritin levels were 
significantly higher in patients with atypical bacterial etiology 
compared with viral etiology. Hepcidin levels were also higher 
in typical bacterial etiology compared with viral etiology.
The ability of hepcidin and ferritin to predict microbial eti-
ology is displayed in Figure 3 by comparing 1 etiological group 
to the 2 other groups combined. High levels of both hepcidin 
and ferritin were associated with a higher risk of atypical bacte-
rial etiology (hepcidin: OR = 2.12, 95% CI = 1.08–4.18, P = .030; 
ferritin: OR = 2.24, 95% CI = 1.29–3.89, P = .004) and a lower 
risk of viral etiology (hepcidin: OR = 0.53, 95% CI = 0.33–0.85, 
P = .009; ferritin: OR = 0.62, 95% CI = 0.39–0.97, P = .035).
We further explored predictive comparisons between single 
etiological groups (Table 2). Ferritin had the ability to discrim-
inate atypical bacterial from both typical bacterial and viral 
etiology but not typical bacterial from viral etiology. Hepcidin 
discriminated both atypical bacterial and typical bacterial eti-
ology from viral etiology but not between the 2 bacterial groups. 
In contrast, iron, transferrin saturation, and soluble transferrin 
receptor were not, or only modestly, associated with microbial 
etiology of CAP.
Multivariate analysis with adjustment for CRP and PCT was 
included, because these are the most studied biomarkers in clin-
ical use for this purpose [21]. Our main findings were largely 
unchanged after adjustment for CRP and PCT in the logistic re-
gression analysis (Table 2). However, the borderline significant 
ability of hepcidin to discriminate between typical bacterial and 
viral microbial etiology in univariate analysis did not sustain.
Association Between the Potential Biomarkers and HFE Genotype
Because genetic variation in the HFE gene may influence 
levels of hepcidin and ferritin, we also analyzed 2 single-
nucleotide variants in the HFE gene, Cys282Tyr (C282Y) 

















































































































Figure 1. Levels of iron and iron-related proteins during the course of pneumonia. Data are shown as median and 25–75 percentiles. Comparison of level at admission and 
6-week follow-up by Wilcoxon signed-rank test. ***, P < .001. Reference ranges in parenthesis: (A) hepcidin (morning levels; women, <0.3–32 ng/mL; men, 0.9–34 ng/mL); 
(B) ferritin (women, 15–200 μg/L; men, 30–400 μg/L); (C) iron (9–34 µmol/L); (D) transferrin (2.0–3.3 g/L); (E) transferrin saturation (women 18–49 years, 10%–50%; women 
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biomarkers to predict HFE genotype during acute-phase 
pneumonia (Supplementary Table 2). Increased levels of 
serum iron and transferrin saturation were associated with 
the 7 cases of potential disease-related genotypes: C282Y/
C282Y and C282Y/H63D. However, we did not find any as-
sociation between hepcidin or ferritin levels and the most 
common heterozygous HFE genotypes, C282Y/WT and 
H63D/WT.
DISCUSSION
All potential biomarkers changed profoundly during the course 
of acute-phase pneumonia, reflecting a high degree of systemic 
inflammation. As expected, serum iron and transferrin satu-
ration were low in the acute phase compared with the 6-week 
follow-up, and they were far below the lower reference limits. 
These findings are consistent with, and probably due to, the 
increase of the main iron regulatory hormone hepcidin [2]. 
Indeed, both hepcidin and ferritin showed an opposite pattern 
with the highest levels at admission.
A major finding of this explorative study was that admis-
sion levels of ferritin predicted atypical bacterial versus typical 
bacterial etiology. Furthermore, levels of both hepcidin and 
ferritin were particularly higher in atypical bacterial etiology 
compared with viral etiology. Accordingly, both hepcidin and 
ferritin showed predictive power of atypical bacterial versus 
viral etiology.
The battle for iron between microbes and host is multifac-
eted, and on an individual level, microbes utilize different strat-
egies to extract iron [22]. The host strategies for withholding 
iron and their effect also vary depending on the intra- or extra-
cellular location of the microbes. The increased levels of ferritin 
and hepcidin in atypical bacterial pneumonia in our study are 
novel observations, supporting diverse mechanisms of iron reg-
ulation depending on pathogen category.
Increased levels of hepcidin is theoretically an indirect 
measure of intracellular iron entrapment, which has been 
shown to promote intracellular pathogen survival and growth 
in vitro [6], a finding supported by studies of cultured macro-
phages [23]. On the other hand, mice studies indicate a 
pathogen-induced downregulation of ferroportin expression 
independent of hepcidin and iron levels [24], and that ele-
vated hepcidin levels may not promote intracellular infections 
[25]. Possible explanations of such hepcidin-independent in-
volvement are specific microbe-induced iron regulation, or a 
compartmentalization of iron within the macrophages, thus 
restricting iron access to intracellular pathogens [8]. Although 
hepcidin is mainly produced in the liver, mice studies suggest 
that infection can induce a peripheral hepcidin production by 





































Figure 2. Levels of iron and iron-related proteins at admission according to microbial etiology. Data are displayed as median and 25–75 percentile. Two-group comparison 
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Figure 3. Forest plots; each etiological group is compared with the other 2 groups. Odds ratios (ORs) are calculated on basis of ln-transformed and standardized values. *, 
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may influence iron availability locally [26–28], but not neces-
sarily change systemic hepcidin levels and iron balance [29]. In 
general, local regulation may differ considerably from the sys-
temic effects assessed by measurement of biomarkers in serum 
[7]. Because iron is tightly bound to transferrin throughout the 
physiological concentration range, it has been argued that the 
primary defense mechanism of hepcidin induction during in-
fection is mainly to prevent NTBI formation that may occur due 
to infection-related destruction of tissue and erythrocytes [25]. 
Nontransferrin-bound iron comprises a heterogeneous group 
of iron species that may be more easily utilizable to pathogens 
than transferrin-bound iron and may enhance growth of some 
microbes [25]. Thus, in addition to withholding iron from 
invading microbes, the hepcidin response during infection may 
protect the host from toxic effects of NTBI [1]. Furthermore, 
in vitro evidence of direct antimicrobial effects of hepcidin has 
been demonstrated, but supporting evidence in vivo in humans 
are yet sparse [5]. Finally, we can only speculate whether the 
hepcidin levels were elevated before or as a consequence of 
atypical bacterial pneumonia. High baseline hepcidin levels 
may theoretically promote atypical bacterial infections.
Because hyperferritinemia may be cytokine-induced or related 
to cellular damage [11, 13], the degree of cellular damage in pneu-
monia as well as the preferred intracellular or extracellular site of 
infection may be important. Hypothetically, the higher level of fer-
ritin in atypical bacterial infections could be related to a more pro-
found cellular damage in this group or be linked to its intracellular 
location. Atypical bacterial infections also differ from other bac-
terial infections of the lung by the prevalence of extrapulmonary 
manifestations [30], and ferritin leakage due to secondary organ 
involvement may contribute to elevated ferritin levels.
It should be noted that the term atypical bacteria is not a 
clearly defined entity [31–33]. The pathogens we included as 
atypical bacteria in this study are either predominantly intra-
cellular (Legionella pneumophila, Mycoplasma pneumoniae, 
Chlamydia pneumoniae) [34] or there is evidence of some de-
gree of intracellular involvement (Bordetella pertussis) [35]. To 
complicate this distinction, the most common CAP pathogen 
S pneumoniae may also occasionally reside intracellularly [36]. 
Nevertheless, we believe that our categorization is sound, and 
we hypothesize that a key point to the particularly increased 
levels of hepcidin and ferritin in atypical pneumonia is their 
dominant intracellular pathophysiology. Viruses are obligate 
intracellular, but, unlike atypical bacteria, their reproduction 
relies entirely on the machinery of the host cells [37]. Although 
the pathophysiological mechanisms resulting in the measured 
levels of hepcidin and ferritin have yet to be detailed, the finding 
of lower hepcidin and ferritin levels among patients with viral 
pneumonia compared with atypical bacterial pneumonia sug-
gest that there are differences in the iron-related immune re-
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More importantly, the abilities of hepcidin and ferritin to 
discriminate between atypical bacterial and viral pneumonia 
were independent of CRP and PCT. Indeed, neither CRP nor 
PCT discriminated between atypical bacterial and viral causes. 
However, as expected, CRP discriminated typical bacterial 
from viral etiology, although by a lower odds ratio than what 
we found for hepcidin and ferritin in predicting atypical bac-
terial etiology. Otherwise, CRP failed to separate the etiolog-
ical groups. Compared with CRP, PCT showed a better ability 
to discriminate between viral and typical bacterial causes. The 
use of a combination of iron-related and traditional inflamma-
tory biomarkers may be a future strategy to predict microbial 
etiology. Because there were no differences in CURB-65 or ICU 
admissions between the etiological groups, we do not believe 
that the differences in biomarker levels between etiological 
groups were related to disease severity.
Although comparative analyses show significant differences, 
the number of patients with an atypical bacterial infection in 
the present study is limited. In addition, being a single-center 
study with specific inclusion and exclusion criteria, the external 
validity to other populations must be carefully considered. The 
microbial etiology of CAP was established through extensive 
microbiological investigations. Still, a definite etiological di-
agnosis was not obtained for 37% of patients, and undetected 
copathogens may have biased the etiological groups. Larger 
studies are needed to validate our findings, preferably with a 
power to distinguish between single pathogens as well as eti-
ological groups, because pathogens within the atypical bacte-
rial group may also be different. Finally, the statistical analyses 
in the present study are used to assess associations and cannot 
prove causal relationships.
CONCLUSIONS
In this prospective cohort of CAP patients, high admission 
levels of ferritin and hepcidin were in particular associated with 
a higher risk of atypical bacterial etiology and a lower risk of 
viral etiology. Hepcidin and ferritin emerge as potential bio-
markers of microbial etiology in CAP.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
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